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Abstract
Background: Antigens encoded in the region of difference (RD) of Mycobacterium tuberculosis constitute a
potential source of specific antigens for immunodiagnosis. In the present study, recombinant protein Rv1985c from
RD2 was cloned, expressed, purified, immunologically characterized and investigated for its potentially diagnostic
value for tuberculosis (TB) infection among BCG-vaccinated individuals.
Methods: T-cell response to Rv1985c was evaluated by IFN-g ELISPOT in 56 TB patients, 20 latent TB infection
(LTBI) and 30 BCG-vaccinated controls in comparison with the commercial T-SPOT. TB kit. Humoral response was
evaluated by ELISA in 117 TB patients, 45 LTBI and 67 BCG-vaccinated controls, including all those who had T-cell
assay, in comparison with a commercial IgG kit.
Results: Rv1985c was specifically recognized by cellular and humoral responses from both TB and LTBI groups
compared with healthy controls. Rv1985c IgG-ELISA achieved 52% and 62% sensitivity respectively, which
outperformed the sensitivity of PATHOZYME-MYCO kit (34%) in detecting active TB (P = 0.011), whereas IFN-g
Rv1985c-ELISPOT achieved 71% and 55% sensitivity in detecting active and LTBI, respectively. Addition of Rv1985c
increased sensitivities of ESAT-6, CFP-10 and ESAT-6/CFP-10 combination in detecting TB from 82.1% to 89.2% (P =
0.125), 67.9% to 87.5% (P < 0.001) and 85.7% to 92.9% (P = 0.125), respectively.
Conclusions: In conclusion, Rv1985c is a novel antigen which can be used to immunologically diagnose TB
infection along with other immunodominant antigens among BCG-vaccinated population.
Background
One-third of the world population is infected with
Mycobacterium tuberculosis. In 2006, there were an esti-
mated 9.2 million new cases of tuberculosis (TB) and
14.4 million prevalent cases of TB [1]. Among people
infected with TB bacilli, about 5-10% will become sick
or infectious at some time during their life [2]. People
with HIV and TB infection are much more likely to
develop active TB [1].
The current TB diagnosis still relies on clinical exami-
nation and radiography, confirmed by sputum smear
microscopy and mycobacterial culture, which often leads
delays in treatment due to slow growth of the mycobac-
teria. Tuberculin skin test (TST) cannot be used as a
specific diagnostic test due to the presence of cross-
reactive antigens with BCG vaccine and other environ-
mental mycobacteria exposure [3,4]. Moreover, accurate
differentiation of latent TB infection (LTBI) from BCG-
vaccinated individuals by TST is difficult. Thus, these
underscore the need for identifying M. tuberculosis spe-
cific antigens and developing rapid, specific as well as
cost-effective diagnostic tests that can differentiate LTBI
from BCG-vaccinated individuals.
Antigens encoded in the region of differentiation (RD)
of M. tuberculosis constitute a potential source of speci-
fic antigens for immunodiagnosis [5-10]. RD2, deleted
from BCG substrains derived from the original BCG
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ORFs and is conserved in all virulent M. tuberculosis.
Among them, Mpt64 and Cfp21 are immunodominant
antigens and have been used as new protective vaccines
and specific diagnostic reagents [9,12-15]. In previous
study, Rv1989c, Rv1978, Rv1981c were investigated for
T cell-based diagnosis of TB [16,17]. Rv1985c, also
encoded by RD2, is a putative transcriptional regulatory
protein. Except that Rv1985c was used in a transcrip-
tional study [18], little is known about the immunogenic
properties of Rv1985c.
The present study was designed to evaluate both
humoral and cellular immune responses to Rv1985c,
encoded in RD2 region of M. tuberculosis, and its ability
to detect active as well as LTBI from BCG-vaccinated
individuals.
Methods
Study population
Blood samples were collected from totally 229 subjects
in this study, which were classified into three groups:
active TB patients (TB group, n = 117), LTBI (LTBI
group, n = 45) and BCG-Denmark vaccinated healthy
controls (HC group, n = 67). The present study is
approved by the Ethics Committee from Huashan Hos-
pital, Fudan University. All individuals are Chinese; all
patients and guidance had given informed consent. The
demographic characteristics of the study populations are
described in Table 1.
Pulmonary TB patients were recruited from TB hospi-
tals in 3 regions of China from Chongqing, Jinan and
Suzhou. The inclusion were made based on the follow-
ing criteria: 1) clinical signs and symptoms including
fever, cough and productive sputum; 2) positive acid-
fast bacilli in sputum smears or positive mycobacterial
culture or a suggestive chest X-ray. Since anti-tuberculo-
sis treatment could affect the response of IFN-g to spe-
cific antigens [4,19-21], patients who received chemical
therapy more than 1 month were excluded from the
T-cell assays.
Forty-five LTBI individuals were recruited based on
the criteria including: 1) close TB contacts that lived
together with TB patient in recent months; 2) positive
T-SPOT®. TB (Oxford Immunotech, UK) test that indi-
cates TB infection; and 3) no clinical signs or symptoms
nor abnormal chest X-ray. All the blood samples were
collected before LTBI were treated.
The control group consisted of healthy subjects
recruited from students and faculties at Fudan Univer-
sity, China, who had received BCG-Denmark vaccination
during childhood and have no history of TB contact.
Individuals with known prior exposure were excluded
and only healthy (no clinical symptoms) and no contact
to TB individuals were collected.
Table 1 The demographic characteristics of the total study population
Groups TB LTBI HC
Description 1. clinical symptom of pulmonary TB 1. very close TB contacts
recently that live together
1. healthy, BCG-
vaccinated controls;
2. positive acid-fast bacilli in sputum smears or positive
mycobacteria culturing or a suggestive chest X-ray
with TB patient
2. positive of T SPOT. TB test
2. no prior M.TB
contact or exposure
3. (for T-cell tests only ) received DOTS therapy less then 1
month
3. no clinical symptom, nor
abnormal chest radiograph
Humoral
response
study
No. of
subjects
117 45 67
Mean age
(yr)
46.4 45.1 34.9
Range of
age (yr)
6-84 16-76 21-68
Male/
female
85/32 13/32 32/35
Cellular
response
study
No. of
subjects
56 20 30
Mean age
(yr)
46.5 43.6 29.6
Range of
age (yr)
11-81 23-74 21-58
Male/
female
35/21 4/16 13/17
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Totally, 56 TB patients, 20 LTBI and 30 healthy controls
had both T-cell assays and antibody tests. Additional 61
TB patients, 25 LTBI and 37 healthy controls only had
antibody tests. T-cell assays include Rv1985c IFN-g ELI-
S P O Ta s s a ya n dac o m p a r a t i v eT - S P O T ® .TB assay,
which use two other immunodominant antigens, 6-kDa
Early Secretory Antigenic Target (ESAT-6) and 10-kDa
Culture Filtrate Protein (CFP-10). Antibody tests include
Enzyme-Linked ImmunoSorbent Assay (ELISA) to
Rv1985c and a comparative commercial PATHOZYME-
MYCO IgG kit (Omega Diagnostics, UK), which uses
two immunodominant antigens, lipoarabinomannan
(LAM) and 38-kDa antigen.
Cloning, expression and purification of Rv1985c
RNA was extracted from stationary phase M. tuberculo-
sis H37Rv cells and cultured in Middlebrook 7H9 med-
ium, as previously described [22]. RT-PCR was
performed to confirm the expression of Rv1985c in M.
tuberculosis, using the ThermoScript RT-PCR system
(Invitrogen, CA, USA), with the specific primers
Rv1985c-F (5′-ATCCATATGGTGGATCCGCAGCTT-
GACGGT) and Rv1985c-R (5′-TATGTCGA-
CACCCGGTCGGCGGCG), according to the
manufacturer′s instructions. NdeI and SalI restriction
sites were incorporated at the 5′-end of the forward and
reverse primers, respectively. The amplicon containing
rv1985c was cloned at the NdeI and SalI sites of pET30a
vectors with a C-terminal six-histidine tag. The con-
struct was verified the correct insert and orientation by
Prism 377 DNA sequencer (Applied Biosystems, War-
rington, UK).
After the construct comprising rv1985c was trans-
formed into Escherichia coli Rosetta (DE3), His-tagged
Rv1985c protein was expressed by 1.0 mM Isopropyl-b-
D-galactopyranoside (Sigma) and purified under native
conditions by His-Bind Column (Novagen) according to
manufacturer’s recommendation. The purified Rv1985c
was dialyzed and stored at -20°C in 25 mM HEPES (pH
7.4) supplemented with 150 mM NaCl, 0.1 mM DMSF
and 10% glycerol. The fractions were also analyzed by
SDS-PAGE and proteins were quantified by Bradford
reagent (Bio-Rad, UK). A HPLC-MS study was applied
to determine purity.
IFN-g ELISPOT assays
Due to limitation of resources, totally 56 TB patients, 20
LTBI and 30 healthy controls accepted and had T-cell
assays simultaneously, which include Rv1985c IFN-g
ELISPOT assay and a comparative T-SPOT®. TB assay.
IFN-g Rv1985c-ELISPOT assay was performed blinded
according to manufacturer’s instruction [23]. A totally
2.5 × 10
5 peripheral blood mononuclear cells (PBMC)
were added in duplicates in micro-wells. Rv1985c was
used at a final concentration of 10 μg/ml (optimized).
PHA mitogen at 5 μg / m lw a se m p l o y e da sap o s i t i v e
control and culture media as negative control. The plate
was incubated at 37°C, 5% CO2 incubator for 20-24 hr.
Positive Rv1985c-ELISPOT test wells were defined as
containing greater than or equal to 6 spots and the
number was at least twice as many spots as the negative
control. For analysis, PHA control wells were required
to have at least 50 SFUs (spot-forming units), and nega-
tive control wells were required to have fewer than
10 SFUs.
The T-SPOT.TB assay enumerating effector T cells
responding to stimulation with ESAT-6-and CFP-10 was
also performed as a comparative ELISPOT method
according to the manufacturer’s instructions [4]. The
spot was counted by technicians blinded to the subject
identifiers using an automated ELISPOT Reader (AID
systems, Germany). According to the manufacturer’s
instructions, either ESAT-6-or CFP-10-stimulated wells
containing greater than or equal to 6 spots with the
number at least twice as many spots as the negative
control were considered positive.
Serological tests
Totally, 117 TB patients, 45 LTBI and 67 healthy con-
trols including all those who had T-cell assay accepted
and had antibody tests simultaneously which include
Rv1985c-ELISA and PATHOZYME-MYCO IgG kit
(Omega Diagnostics, UK). IgG-and IgM-ELISA was per-
formed to determine the humoral immune response to
recombinant Rv1985c by 96-well microtitre plates as
previously described [24]. Microtitre plates were coated
with 0.5 μg/100 μl of Rv1985c. The sera were diluted
500-fold for IgG-ELISA and 100-fold for IgM-ELISA,
distributed in microtitre plates and incubated for 1 h at
37°C. Each serum was repeated three times. The IgG-
and IgM-ELISA results were analyzed using cut-off
values equal to the mean OD for the healthy control
serum samples plus two standard deviations. Any sam-
ple exhibiting absorbance above the cut-off value was
considered positive.
The PATHOZYME-MYCO IgG kit measuring the
level of IgG antibody to two antigens, LAM and 38-kDa
antigen was also performed as a comparison. The assay
was done according to manufacturer’s recommendation
as described previously [25,26]. Four standards (with 2,
4, 8 and 16 sero-units/ml) were provided for generation
of a semi-logarithmic reference curve. The units result
was interpreted by extrapolating the optical density
(OD) from the curve and multiplying by 100 (diluted 1/
100). According to the manufacturer’s instructions, sera
of higher than 400 units/ml were considered IgG-
positive.
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For statistical analysis, the OD differences among groups
were calculated by one-way ANOVA Newman-Keuls
test. The SFU difference of among groups was analyzed
by Kruskale-Wallis one-way analysis Dunn’s post-test.
The sensitivities of different tests were analyzed by
McNemar’s chi-square test. In all analysis, P values ≤
0.05 were considered statistically significant.
Results
Expression and purification of M. tuberculosis Rv1985c
protein
The expression of Rv1985c at the mRNA level was veri-
fied by RT-PCR study. An expected 930-bp PCR product
was revealed by 1.0% agarose gel electrophoresis, and no
PCR product was detected in the absence of reverse tran-
scriptase. These data indicated that Rv1985c was
expressed during the growth in vitro (data not shown).
The recombinant Rv1985c containing a minimal C-
terminal 6-Histidine tag verified by probing with mono-
clonal anti-His tag antibody (data not shown) was largely
present in the supernatant fraction. The purified protein
y i e l d e d4 . 1m g / l i t e ro fc u l t u r ea n das i n g l e3 4 - k D ap r o -
tein was observed in SDS-PAGE gel (Figure 1A). HPLC
analysis confirmed the purity of the protein to 98.7%.
The approximate molecular weight for recombinant
Rv1985c was 33.892 kDa (Figure 1B), which is in accor-
dance with the theoretical mass prediction of 33.886 kDa.
Specific T-cell response to Rv1985c in TB and LTBI groups
compared with healthy controls
The SFU of TB and LTBI groups were significantly
higher than that of HC group (P < 0.001) (Figure 2),
indicating PBMC from both TB and LTBI groups devel-
oped stronger T-cell responses than those of control
g r o u p .H o w e v e r ,n os t a t i s t i cd i f f e r e n c ei nS F Uw a s
observed between TB and LTBI groups (P = 0.25). Fig-
u r e3s h o w e dt h eR O Cc u r v eo fR v 1 9 8 5 c ,w h i c h
described the relationship between the sensitivity and
Figure 1 Purification and analysis of recombinant Rv1985c. (A) Electrophoresis analysis on a 12% SDS-PAGE gel stained with Coomassie
blue; Lane 1, Takara low molecular weight marker; Lane 2, crude E. coli supernatant fraction before application to column (induced with IPTG);
Lane 3, flow-through fraction of His-bind resin; Lane 4, fraction washed with 120 mM imidazole; Lane 5, fraction eluted with 250 mM imidazole.
Molecular weight of Rv1985c is approximately 33.8 kDa and protein marker sizes are indicated on the side of gel. (B) Mass-fingerprinting protein
assay of 33.9-kDa by MALDITOF.
Figure 2 ELISPOT showed that PBMC from both TB and LTBI
groups developed stronger IFN-g producing response to
Rv1985c antigens than those from HC (healthy controls) group.
PBMC from TB, LTBI, and HC individuals were stimulated overnight
with recombinant Rv1985c and IFN-g producing T cells were
detected by ELISPOT. Results of individual response are expressed as
spot forming units (SFU) per 2.5 × 10
5 PBMCs. Horizontal lines
indicate the median of SFU of each group. SFU greater than or
equal to 6 was considered positive (indicated by the dotted line). P-
values of SFU difference between either two groups were shown
above the plots determined by Kruskale-Wallis one-way analysis
Dunn’s post-test. ***, P < 0.001; **, P < 0.01; *, P < 0.05; NS: P-value
is not significant.
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0.836 (95% CI, 0.746-0.927). The cut-off level was set at
4.5, giving the optimal combination of sensitivity and
specificity. Using the cut-off level, 40/56 (71%) TB
patients, 11/20 LTBI (55%), and 1/30 controls (3%) were
positive by the T-cell assay.
Comparison of Rv1985c-ELISPOT test with T-SPOT. TB
Test
T-SPOT.TB test was performed comparatively in the
same category groups. Totally 46 patients (82.1%) had
positive responses to ESAT-6 and 38 (67.9%) had posi-
tive responses to CFP-10 (Table 2). In contrast, none of
healthy controls had positive result. In this study, T-
SPOT. TB achieved 85.7% sensitivity (either positive to
ESAT-6 or CFP-10).
Compared with the sensitivity of Rv1985c (71%) in
detecting active TB, ESAT-6 and CFP-10 had the
equivalent sensitivity level (P = 0.18 and 0.82 respec-
tively). Both ESAT-6 and CFP-10 showed similarly
high specificity (both 100%) compared with Rv1985c
(96.7%) without statistically significantd i f f e r e n c e .
However, the strength of T-cell response to Rv1985c
was lower than those of ESAT-6 and CFP-10 (both P <
0.05).
To maximize the sensitivity of a future diagnostic
reagent, we investigated to combine Rv1985c with
ESAT-6 and CFP-10 in TB detection. The results
showed addition of Rv1985c increased the sensitivity of
single antigen ESAT-6, CFP-10 and combined antigens
of ESAT-6/CFP-10 in detecting TB from 82.1% to 89.2%
(P = 0.125), 67.9% to 87.5% (P < 0.001) and 85.7% to
92.9% (P = 0.125), respectively.
Serological response to Rv1985c in TB and LTBI groups
compared with healthy controls
Figure 4 showed the IgG (4A) and IgM (4B) antibody
OD values to Rv1985c obtained from 117 TB patients,
45 LTBI and 67 healthy controls. The data demon-
s t r a t e dt h a tt h es e r af r o mT Ba n dL T B Ig r o u p sh a d
higher IgG antibody responses than those from HC
group (p <0.0001) (Figure 4A). However, only TB group
(P = 0.040) but not LTBI group (P = 0.97) had signifi-
cantly higher IgM response than that in healthy donors
(Figure 4B).
Totally, 61 of 117 TB patients, 28 of 45 LTBI and 2 of
67 HC had greater IgG values than the cut-off values,
whereas only 23 of 117 TB patients, 5 of 45 LTBI and 2
of 67 HC had greater IgM value than the cut-off values
(Figure 4). The sensitivity of Rv1985c-ELISA IgG in
detecting TB and LTBI were 52.1% and 62.2% respec-
tively, and the sensitivities of Rv1985c-ELISA IgM in
detecting TB and LTBI were 19.7% and 11.1%, respec-
tively (Table 3). The specificity of Rv1985c-IgG and
Rv1985c-IgM response in healthy controls was both
97.0%. IgG antibody responses to Rv1985c were
observed stronger and more specific than IgM antibody
responses (Figure 4), and serum sample of IgG test were
diluted 1:500 (optimized) instead of 1:100.
Rv1985c-IgG ELISA in Comparison with PATHOZYME-
MYCO IgG kit
To better evaluate the humoral antigenic feature of
Rv1985c, the IgG response was compared with the com-
mercial PATHOZYME-MYCO ELISA IgG kit for diag-
nosis of active TB. The sensitivity and specificity of
PATHOZYME-MYCO IgG kit in the detection of active
TB were 34.2% and 98.5%, respectively. Comparing with
Rv1985c-IgG ELISA, PATHOZYME-MYCO IgG test
had lower sensitivity (34.2%) than Rv1985c-IgG ELISA
(52.1%) in detecting TB with significant difference by
McNemar chi-square test (P = 0.011) (Table 3).
Discussion
In the present study, cloning, expression, purification
and both humoral and cellular immune responses to
recombinant antigen Rv1985c of M. tuberculosis were
evaluated for the first time in active TB patients, LTBI
individuals and BCG-vaccinated healthy controls.
Rv1985c was specifically recognized by both cellular and
humoral responses from the TB and LTBI groups com-
pared with the healthy controls. IFN-g Rv1985c-ELI-
SPOT achieved 71% and 55% sensitivity in detecting
active and latent TB, respectively, and 96.7% specificity
in healthy controls in this test, whereas Rv1985c-ELISA
IgG achieved 52% and 62% sensitivity in detecting active
and latent TB, respectively, and 97.0% specificity in the
healthy controls. Since one-third of population is
Figure 3 Receiver-operator characteristics (ROC) curve for
Rv1985c for diagnosis of active TB by T-cell response. The
curve describes the association between sensitivity and specificity at
different thresholds of the study.
Chen et al. BMC Infectious Diseases 2010, 10:273
http://www.biomedcentral.com/1471-2334/10/273
Page 5 of 9infected with TB in the world, especially in high epi-
demic region, it would therefore be meaningful if a
cost-effective and sensitive sero-diagnostic test capable
of identifying LTBI from healthy controls could be
developed. To some extent, data showing that Rv1985c-
IgG ELISA achieved a sensitivity of 62% in detecting
LTBI and could distinguish LTBI from healthy BCG-
vaccinated individuals is promising.
In the study, latently infected individual was deter-
mined by measurement of T-SPOT TB instead of TST
in high risk BCG-vaccinated population. Specific cellular
response to Rv1985c can be found not only in indivi-
duals with active TB disease, but also in individuals with
latent M. tuberculosis infection. Recently, antigen TB 7.7
and Rv3879c were determined to increase diagnostic
sensitivity in Quantiferon TB Gold In-tube and T-
SPOT. TB assays when used in combination with
ESAT6 and CFP10 [27,28]. Since the T-cell response to
Rv1985c had equivalent sensitivity to CFP-10 and
E S A T - 6 ,i ti sv e r yp o s s i b l et oi m p r o v et h ed i a g n o s t i c
performance of ESAT-6 and/or CFP-10 by addition of
Rv1985c. Though the additive effect made for ESAT-6
Table 2 Characterization of IFN-g ELISPOT in response to recombinant Rv1985c and the peptides mixture from ESAT-6
and CFP-10 in TB patients, LTBI and Healthy controls groups
TB (n = 56) LTBI (n = 20) HC (n = 30)
Antigens Mean
SFU
±
standard
error
No.
positive
1
Sensitivity
2
(%)
95%
CI (%)
Mean
SFU
±
standard
error
No.
positive
1
Sensitivity
3
(%)
95%
CI (%)
Mean
SFU
±
standard
error
No.
positive
1
Specificity
4
(%)
95%
CI (%)
Rv1985c 19.3 ± 4.7 40 71.4 57.8
to
82.7
10.0 ± 2.8 11 55 31.1
to
78.9
2.6 ± 1.1 1 96.7 82.8 to
99.9
ESAT-6 66.59 ±
9.3
5
46 82.1
6 70.6
to
91.2
37.6 ±
12.0
15 75 54.2
to
95.8
0.77 ±
0.20
0 100.0 88.4 to
100.0
CFP-10 132.8 ±
22.2
5
38 67.9
7 54.9
to
80.2
77.9 ±
24.0
15 75 54.2
to
95.8
1.0 ± 0.25 0 100.0 88.4 to
100.0
1: Positive was defined as SFU greater than or equal to 6 in 2.5 × 10
5 cells for ESAT-6 and CFP-10, and greater than 4.5 in 2.5 × 10
5 cells for Rv1985c;
2: Percentage of responding patients out of all TB patients tested;
3: Percentage of responding individuals out of all LTBI tested;
4: Percentage of true-negative healthy controls out of all healthy control individuals tested;
5: Statistically higher SFU than SFU of Rv1985c by two-tailed paired Mann-Whitney test, p < 0.001;
6: Statistical significance was determined in respect to sensitivity of Rv1985c by McNemar chi-square test, p = 0.02;
7: Not significant in respect to sensitivity of Rv1985c by McNemar chi-square test, p = 0.52.
Figure 4 Comparison of antibody IgG (4-A) and IgM (4-B) responses to recombinant protein Rv1985c among different categories of
TB patients, LTBI and HC. Dotted lines on each group indicate the median value. Horizontal lines on each graph indicate the cut-off value,
which was determined by the mean absorbance plus 2 SD by use of healthy control sera. P-values of absorbance difference between either two
groups were shown above the plots determined by one-way ANOVA Newman-Keuls test. ***, P < 0.001; **, P < 0.01; *, P < 0.05; NS: P-value is
not significant.
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nificant among 56 TB patients, the combination of
Rv1985c with CFP-10 could improve sensitivity of CFP-
10 with statistical significance and the specificity
remained equivalently high.
I na d d i t i o n ,t oe v a l u a t et h ea n t i g e n i cf e a t u r eo f
Rv1985c, both T-cell response and B-cell response to
Rv1985c were compared with other antigens. Compared
Rv1985c IgG-antibody response with PATHOZYME-
MYCO IgG kit, Rv1985c showed higher sensitivity than
LAM and 38-kDa antigens in diagnosing active TB, sug-
gesting that Rv1985c may be a better serodiagnostic
reagent than LAM and 38-kDa in terms of distinguish-
ing TB patients from healthy BCG-vaccinated indivi-
duals. Although a sensitivity of 52% is not high enough
as a stand-alone serodiagnostic test for TB, it could be
used with other immunodominant antigens in combina-
tion. When Rv1985c-IgG tests were combined with
Rv1985c-IgM tests, the sensitivity was improved from
52.1% to 61.4% (P < 0.001) with equivalent high specifi-
city (95.5%) (Table 3). The combination of Rv1985c and
PATHOZYME-MYCO IgG yielded 70% sensitivity,
which is similar to TST (77%) [29]. Since the specificity
of the combination (96%) was superior to TST (59%) in
BCG-vaccinated population [29], this system could be
used to replace TST. It is also noted that the sensitivity
of PATHOZYME-MYCO IgG (34%) was slightly lower
than the other studies, ranged from 41% to 49%
[26,30,31]. Since the serological response to a specific
antigen often depends on the geographical location and
ethnic background of the population being studied [32],
the observed small variation in performance of PATHO-
ZYME-MYCO IgG is understandable.
It is known that T-cell response to most immunodo-
minant antigens of M. tuberculosis, like ESAT-6 and
CFP-10, could not differentiate active TB infection with
latent infection [29]. However, whether humoral
response to immunodominant antigens can differentiate
active TB infection with LTBI is less known [33]. On
the basis of our data showing that no statistical differ-
ence was observed between TB and LTBI groups in
humoral response against Rv1985c, we suggest that the
humoral response to some immunodominant antigens
could either not be able to differentiate active TB with
LTBI. Consistently, a recent study showed that ESAT-6
and CFP-10 antibodies are present not only in active TB
patients but also in latent infection individuals, particu-
larly in areas with high levels of exposure to M. tubercu-
losis [33]. These studies may underlie the insufficient
specificity of the sero-diagnostic tests designed to detect
active TB and used in TB epidemic regions [30,34,35].
Surprisingly, the humoral response to Rv1985c did not
correlate at all with the cellular response (P = 0.87) in
the LTBI group. A possible explanation is that person-
to-person variation of antigen recognition, rather than
recognition of particular antigens, is the key attribute of
humoral immunity in TB [36].
Since RD2 is absent in BCG strains acquired from the
Pasteur Institute after 1931, including vaccine
BCG-Phipps, BCG-Tice, BCG-Frappier, BCG-Prague,
BCG-Connaught, BCG-Glaxo, BCG-Pasteur and BCG-
Denmark, which is now widely used in China, Rv1985c
is not expected to be cross-reactive [11]. However, we
observed 1/30 healthy subjects had positive Rv1985c-
ELISPOT response and 2/67 had positive IgG-antibody
response to Rv1985c. Rv1985c is a putative lysR protein
encoded by RD2 region of the M. tuberculosis genome.
Rv1985c may be present in a few BCG, such as BCG-
Russia, BCG-Moreau, BCG-Japan, BCG-Sweden and
some NTM strains [11], which may cause some immune
response to the antigen and underlie the 3% positive
response in healthy controls in both tests. It should also
be noted that the T-cell response of Rv1985c was
weaker than those of RD1-encoded antigens. Some
Table 3 Seroreactivity of recombinant proteins in sera from TB patients, LTBI and HC
TB (n = 117) LTBI (n = 45) HC (n = 67)
Antigens No. Positive
1 Sensitivity
2 (%) No. Positive
1 Sensitivity
3 (%) No. Positive
1 Specificity
4 (%)
PATHOZYME-MYCO IgG 40 34.2 NT NT 1 98.5
Rv1985c IgG 61 52.1
5 28 62.2% 2 97.0
Rv1985c IgM 23 19.7 5 11.1% 2 97.0
Rv1985c IgG + IgM 73 62.4
5 29 64.4% 3 95.5
Rv1985c+ PATHOZYME-MYCO IgG 82 70.1
5 NT NT 3 95.5
1: For 1985c positive sera, defined as cases for which the optical density (OD) generated by the serum was greater than the mean OD of the healthy control sera
plus two standard deviations. For PATHOZYME-MYCO IgG positive sera, defined as cases of more than 400 units per ml, which was calculated by extrapolating
the OD from the standard curve and multiplying by 100;
2: Percentage of responding patients out of all TB patients tested;
3: Percentage of responding patients out of all LTBI tested;
4: Percentage of true-negative healthy controls out of all healthy control individuals tested;
5: Statistical significance was determined in respect to sensitivity of PATHOZYME-MYCO IgG by McNemar chi-square test, p < 0.01;
NT: not tested.
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Page 7 of 9individuals were just above the cut-off value. According
to the recent T-SPOT. TB guild of diagnosing TB infec-
tion, when spot count is 5, 6 or 7, the results should be
considered borderline or equivocal. If we use this cri-
teria in Rv1985c, 10 of 56 (18%) TB and 2 of 21 (10%)
LTBI individuals of Rv1985c-ELISPOT assay should be
interpreted as borderline, which reflects relative weak-
ness of the T-cell response of the antigen.
Furthermore, because of the difficulty in recruit, three
groups were recruited from different areas. TB and
LTBI were recruited from Chongqing, Jinan and Suzhou,
whereas the HC were from Shanghai. Although same in
ethnics, different in age and areas could result in differ-
ence in background immune responses, which could
affect the cut-off levels and consequently the sensitivity
and specificity of the assays.
Finally, since LTBI was partly defined by a positive T-
SPOT.TB, to compare Rv1985c-ELISPOT with T-SPOT.
TB to evaluate the antigen in diagnosing LTBI has some
drawbacks. Thus, due to lack of a reference standard,
we didn’t compare the two assays in diagnosing LTBI.
The value of the antigen should be better recognized
and evaluated by prognostic study, such as predicting
subsequent development of active TB disease [37,38].
Because this is the first study to evaluate Rv1985c,
further validation on diagnostic criteria is still required.
Conclusions
In conclusion, Rv1985c it a novel antigen which is speci-
fically recognized by cellular and humoral responses
from both TB and LTBI individuals compared with
healthy individuals. Reactivity towards Rv1985c can be
used to immunologically diagnose TB infection indivi-
duals along with other immunodominant antigens
among BCG-vaccinated population.
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